ClinicalTrials.gg
Active, not recruitingNCT04577755Updated Nov 18, 2026

Pomalidomide Treatment in Patients With Kaposi Sarcoma

A Phase 2 interventional study of Biopsy Procedure and Biospecimen Collection in Skin Kaposi Sarcoma, sponsored by National Cancer Institute (NCI). Active, not recruiting at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know

Updated Sep 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Sarcoma, Kaposi by National Cancer Institute (NCI) — 8 open to participants now, 12 under way, none of them phase 3. Sarcoma, Kaposi · National Cancer Institute (NCI).

Planned enrollment
10th of 22
45 · median 39
Started
2022
the only one that year
Phase 2
10 of 36
2 open now
Primary completion
2027-02
later than 2 of 10 live
Registered
30th of 36
by date

Among the 36 studies in Sarcoma, Kaposi by National Cancer Institute (NCI), this one is the 10th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2022, is one of 10 in phase 2, reaches primary completion later than 2 of the 10 other live ones, and was the 30th registered.

Sarcoma, Kaposi

161 studies on the registry are indexed under Sarcoma, Kaposi; 24 are open to participants now.

Browse Sarcoma, Kaposi studies →

Open to participants now

8 of the 36 studies in Sarcoma, Kaposi by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 21 Sarcoma, Kaposi studies recruiting now, 11 (52%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Sarcoma, Kaposi by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.

Read the detailed description

PRIMARY OBJECTIVE:

I. To assess the proportion of participants with Kaposi sarcoma (KS) (with or without human immunodeficiency virus [HIV], regardless of previous treatment status) treated with pomalidomide who respond to treatment with a durable response (i.e., response duration of at least one year).

SECONDARY OBJECTIVES:

I. To measure the overall response rate (ORR) and report 95% confidence intervals in the overall study population.

Ia. To measure the ORR in the HIV positive study population. Ib. To measure the ORR in the HIV unrelated study population. II. To estimate the ORR in subgroups of KS in regard to HIV and previous treatment status.

III. To assess the safety of pomalidomide therapy. IV. To describe changes in visceral disease among those presenting with evaluable visceral disease.

V. To assess response duration in participants treated with pomalidomide.

EXPLORATORY OBJECTIVES:

I. To assess the effect of pomalidomide treatment on the tumor microenvironment and explore the relationship with clinical response.

II. To describe the effects of pomalidomide on CD4 lymphocyte counts and HIV viral load in HIV positive (+) participants.

III. To assess the effect of pomalidomide treatment on serum biomarkers and explore the relationship with clinical response.

IV. To assess Kaposi's sarcoma-associated herpesvirus (KSHV) viral copy number in plasma and explore whether changes correlate with clinical outcome.

V. To assess the effects of pomalidomide on viral and cellular transcription in KS tumor biopsies and explore the relationship with clinical response.

VI. To biobank clinical samples for future potential studies on the immune phenotype and viral and cellular transcription and to explore the relationship with clinical response.

OUTLINE:

Patients receive pomalidomide orally (PO) once daily (QD) on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients with complete response (CR) or partial response (PR) continue pomalidomide for an additional 12 cycles with the option to continue thereafter in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients with stable disease may continue pomalidomide for an additional 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray imaging throughout the trial. Patients may undergo computed tomography (CT) as clinically indicated. Patients also undergo blood sample collection and may optionally undergo tissue biopsy during screening and on the trial.

After completion of study treatment, patients are followed up every 6 months for up to 5 years.

03

Conditions studied

  • Skin Kaposi Sarcoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is able to understand and willing to sign a written document
  • Participants must have or cytologically confirmed cutaneous KS. Participants must have with a minimum of five bi-dimensionally measurable KS cutaneous marker lesions. If fewer than five bi-dimensionally measurable marker lesions are available, the total surface area of the marker lesion(s) must be >= 700 mm\^2
  • Participants must have documentation of status

    • If HIV negative, documentation of a negative HIV rapid test within 21 days before enrollment into OPEN Step-1 (Treatment Assignment - Registration Step).
    • If HIV positive, documentation of HIV-1 infection by means of any one of the following:

      • Documentation of HIV diagnosis in the medical record by a licensed health care provider
      • Documentation of receipt of antiretroviral therapy (ART) (at least two different medications that do not constitute a prescription for pre-exposure prophylaxis [PrEP]) by a licensed health care provider. Documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name
      • Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multi-spot antibody differentiation assay
    • Note: The term "licensed" refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally (e.g., United States [U.S.] Food and Drug Administration [FDA])
    • WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an enzyme (E)/carbon immunoassay (CIA) that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 ribonucleic acid (RNA) viral load
  • Age >= 18 years. Because no dosing or adverse event data are currently available on the use of pomalidomide in participants \< 18 years of age, children are excluded from this study
  • (ECOG) performance status =\< 1
  • of greater than 6 months
  • >= 8 g/dL (within 14 days before enrollment into OPEN Step-1 (Treatment Assignment - Registration Step)
  • (ANC): >= 1,000/mm\^3 (within 14 days before enrollment into OPEN Step-1 (Treatment Assignment - Registration Step)
  • : >= 75,000/mm\^3 (within 14 days before enrollment into OPEN Step-1 (Treatment Assignment - Registration Step)
  • =\< 1.5: x (ULN) unless the patient is receiving an ART drug known to be associated with increased bilirubin, in which case the direct fraction should be =\< 2 x ULN (within 14 days before enrollment into OPEN Step-1 (Treatment Assignment - Registration Step)
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =\< 2.5 x institutional ULN (within 14 days before enrollment into OPEN Step-1 (Treatment Assignment - Registration Step)
  • Serum creatinine =\< 2.0 mg/dL/176.8 umol/L; or estimated >= 15 mL/minute (1.00 mL/s) (as calculated per the Cockcroft-Gault equation (within 14 days before enrollment into OPEN Step-1 (Treatment Assignment - Registration Step)
  • Females of (FCBP), defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally post menopausal for at least 24 consecutive months, i.e., has had menses at any time in the preceding 24 consecutive months) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days prior to and again within 24 hours of starting pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of , one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy. All patients must be counseled at a minimum of every 28 (± 2) days about pregnancy precautions and risks of fetal exposure
  • HIV positive participants must be taking stable ART for >= 12 weeks, and have an undetectable HIV viral load within 28 days before enrollment into OPEN Step-1 (Treatment Assignment - Registration Step). Minor fluctuations up to 200 copies/mL are acceptable
  • HIV positive participants must not show recent improvement on ART that may confound response evaluation, within the following parameters:

    • If on ART 12 to 24 weeks, participants must show evidence of KS progression requiring further systemic treatment

      • Evidence of KS progression for eligibility include: Any new lesion(s); spreading of lesions by any measurable degree; development of ulceration; worsening edema documented by circumferential measure of limb or body; increase in symptoms such as pain, including negative psychological impact, requiring; any degree disease worsening by imagining) that would prompt expert assessment to recommend further systemic treatment without delay
    • If on ART for > 24 weeks, must show no evidence of regression in last 8 weeks

      • Evidence of KS regression for eligibility include: Measures of edema, lesion size or number, resolution of ulceration, or 20% improvement by imaging in largest diameter. For purposes of this assessment, if there is 20% reduction in size of any lesion, disappearance of any lesion, this constitutes regression unless there is concomitant increase in size or appearance of new lesions elsewhere
  • Participants must agree to participate in and comply with the mandatory POMALYST Risk Evaluation and Mitigation Strategy (REMS) program
  • Participants must be able to take aspirin 81 mg daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA], may use one of the alternatives
  • For participants with impaired decision-making capacity (IDMC): Participants with IDMC may be eligible for the study provided all other eligibility criteria are satisfied:

    • The participant's legally authorized representative (LAR) is able and willing to sign consent in addition to the study candidate
    • Both participant and LAR agree to follow study parameters and ensure that drug is taken per protocol, recorded in the study drug diary, and returned to clinic with any unused pills

Exclusion criteria

Exclusion Criteria:

  • Participant who is receiving any other agents
  • Participant has symptomatic visceral KS involving the lungs or gastrointestinal (GI) tract that requires immediate chemotherapy or radiotherapy. Participants with minimally symptomatic visceral disease not requiring immediate tumor shrinkage are eligible if in provider judgment potential disease progression will not cause a hazard for the participant
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide
  • Use of agents containing zidovudine (including Combivir and Trizivir) are prohibited. Changes to ART therapy during the study may be made if medically necessary (toxicity, failure of regimen, etc.). Use of medications or substances that are strong inhibitors of cytochrome P450 (CYP)1A2, which include amiodarone, cimetidine, fluoroquinolones (e.g., ciprofloxacin, enoxacin), fluvoxamine, and ticlopidine is prohibited. Co-administration of efavirenz, an inhibitor of CYP1A2, with strong inhibitors of and P-glycoprotein (P-gp) is prohibited. Use of erythropoietin is prohibited. Co-administration of greater than doses required for treatment of adrenal insufficiency is prohibited. Because the lists of these agents are constantly changing, it is important to regularly consult frequently updated list; medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the /enrollment procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection for which the participants have not completed at least 14 days of therapy prior to study enrollment into OPEN Step-1 (Treatment Assignment - Registration Step) and/or is not clinically stable
  • Participant has symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements
  • Pregnant women are excluded from this study because pomalidomide is a thalidomide analog with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pomalidomide, breastfeeding should be discontinued if the mother is treated with pomalidomide
  • Participants who have had chemotherapy, radiotherapy, or therapies to target KS lesions within 4 weeks (6 weeks for nitrosoureas or mitomycin C) with the exception of ART, before enrollment into OPEN Step-1 (Treatment Assignment - Registration Step)
  • Participants with high clinical suspicion of concurrent Castleman disease or IL6 related inflammatory disease

    • For a reference of signs and symptoms consistent with IL6 related inflammatory disease or KSHV inflammatory cytokine syndrome (KICS) can refer to publication from Polizzotto Minnesota (MN), et al. Clinical Features and Outcomes of Patients with Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KICS. Clinical Infectious Diseases, 2016. 62(6):730-8
  • Participants with a history of malignant tumors other than KS, unless:

    • In complete remission for >= 1 year, or
    • Completely resected basal cell or squamous skin carcinoma, or
    • In situ squamous cell carcinoma (SCC) of the cervix or anus
  • Participants with grade >= 3 peripheral neuropathy
  • Participants with a history of venous or arterial thromboembolism, unless line-rated thrombosis without embolus occurring >= 1 year prior to study entry
  • Participants with a known procoagulant disorder including prothrombin gene mutation 20210, antithrombin III deficiency, protein C deficiency, protein S deficiency, or antiphospholipid syndrome, but not including heterozygosity for the Factor V Leiden mutation or the presence of a lupus anticoagulant in the absence of other criteria for the antiphospholipid syndrome
  • Participants with any prior use of pomalidomide, lenalidomide or thalidomide
  • Participants with any condition, including the presence of laboratory abnormalities, which in the opinion of the responsible investigator places the participant at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Treatment (pomalidomide)

    Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients with CR or PR continue pomalidomide for an additional 12 cycles with the option to continue thereafter in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients with stable disease may continue pomalidomide for an additional 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray imaging throughout the trial. Patients may undergo CT as clinically indicated. Patients also undergo blood sample collection and may optionally undergo tissue biopsy during screening and on the trial.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Pomalidomide · Procedure: X-Ray Imaging

Interventions

  • ProcedureBiopsy Procedure

    Undergo tissue biopsy

    Also known as: Biopsy, BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given PO

    Also known as: 4-Aminothalidomide, Actimid, CC 4047, CC-4047, CC4047, Imnovid, Pomalyst

  • ProcedureX-Ray Imaging

    Undergo x-ray imaging

    Also known as: Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

06

What researchers measure

Primary outcomes

  1. Duration of response

    The Kaplan-Meier (K-M) method will be used to describe duration of response for all treated participants. The cumulative proportion of study participants still in response at one year will be estimated using the point estimate and the 95% confidence interval using Greenwood's formula for the standard error of the K-M estimate. The proportional hazards model will be used to evaluate the association of human immunodeficiency virus (HIV) status and pretreatment status on duration of response.

    Time frame: From the first date at which a partial or complete response is documented until progression or death due to any cause, assessed up to 5 years

Secondary outcomes

  1. Overall response rate (ORR)

    The binomial proportion and its 95% confidence interval will be used to estimate ORR in four groups defined by HIV status and pretreatment status (HIV+, pretreated; HIV+, treatment naive; HIV-, pretreated and HIV-, treatment naive). In addition, the binomial proportion and its 95% confidence interval will be used to describe the ORR for HIV+ and HIV- participants, and those that were pretreated and treatment naïve.

    Time frame: Up to 5 years post treatment

  2. Incidence of adverse events

    Will be assessed using version Common Terminology Criteria for Adverse Events 5.0. Adverse events observed on this study will be summarized by organ system, severity grade and relationship to pomalidomide. Frequency and severity of adverse events will be tabulated at the event and person level.

    Time frame: Up to 5 years post treatment

  3. Changes in visceral disease

    For those with evaluable visceral disease, changes in visceral disease will be descriptively reported.

    Time frame: Baseline up to 5 years post treatment

  4. Response duration in participants treated with pomalidomide

    For deaths unrelated to progressive disease, duration of response will be censored at the date of the last Kaposi sarcoma (KS) evaluation during which the participant was determined to still be in response.

    Time frame: From the first date of which a partial or complete response is documented until first date of progression, assessed up to 5 years

Other outcomes

  1. Effect of treatment on changes in tumor microenvironment

    Will assess the effect of pomalidomide treatment on the tumor microenvironment and explore the relationship with clinical response and summarize over time. Descriptive statistics for changes in tumor micro-environment will be calculated for all participants and according to clinical response to examine pre- and post-treatment differences and to explore the relationship with clinical response. Changes from baseline will be explored with one-sample nonparametric tests.

    Time frame: Baseline up to 5 years post treatment

  2. Effect of pomalidomide on CD4 lymphocyte counts

    Will be summarized over time.

    Time frame: Up to within 7 days of treatment discontinuation

  3. Effect of pomalidomide on HIV viral load

    Will be summarized over time.

    Time frame: Up to within 7 days of treatment discontinuation

  4. Change in Kaposi's sarcoma-associated herpesvirus (KSHV) viral copy number

    Will assess KSHV viral copy number in plasma and explore whether changes correlate with clinical outcome and summarize this data over time. Descriptive statistics for changes in KSHV viral copy number will be calculated for all patients and according to clinical response to examine pre- and post-treatment differences and to explore the relationship with clinical response. Changes from baseline will be explored with one-sample nonparametric tests

    Time frame: Baseline up to within 7 days of treatment discontinuation

  5. Effect of pomalidomide on change in serum biomarkers

    Will assess the effect of pomalidomide treatment on serum biomarkers and explore the relationship with clinical response and summarize this data over time. Descriptive statistics for changes in serum biomarkers will be calculated for all patients and according to clinical response to examine pre- and post-treatment differences and to explore the relationship with clinical response. Changes from baseline will be explored with one-sample nonparametric tests.

    Time frame: Baseline up to within 7 days of treatment discontinuation

  6. Effects of pomalidomide on viral and cellular transcription

    Time frame: Baseline up to within 7 days of treatment discontinuation

  7. Biobank clinical samples

    Time frame: Up to study completion

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Feb 2027, 58 months after the start.

Of 22 phase 2 interventional studies under Sarcoma, Kaposi, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 84. This study's planned 58 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Oct 2026 → Feb 2027 and completion Oct 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2020
First posted
Oct 8, 2020
StartActual
Mar 18, 2022
Primary completionEst.
Feb 4, 2027was Oct 2026
CompletionEst.
Feb 4, 2027was Oct 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2026→Feb 4, 2027
Sep 28, 2026
Study completion
Oct 1, 2026→Feb 4, 2027
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Primary completion Oct 1, 2026→Feb 4, 2027
    Study completion Oct 1, 2026→Feb 4, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04577755
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Mar 18, 2022
Primary completion
Feb 4, 2027 (estimated)
Completion
Feb 4, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Samantha L Vogt
principal investigator · AIDS Malignancy Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion